Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01084824 · ClinicalTrials.gov registry record · NA
A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin
A NA study of Verruca Vulgaris, sponsored by North Idaho Dermatology.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT01084824 is a NA study of Verruca Vulgaris that has completed, run by North Idaho Dermatology. The registered enrollment target is 70 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01084824, a NA study of Verruca Vulgaris, has completed, sponsored by North Idaho Dermatology.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study was to see if liquid nitrogen, a commonly used treatment for warts, is more effective if it is used alone, or if it is more effective if combined with cantharidin, a topical treatment also commonly used for warts (verruca vulgaris).
Conditions Studied
Interventions
- DRUG Liquid nitrogen and cantharidin
- DRUG Liquid nitrogen and topical placebo
Study Locations (1)
Idaho
- North Idaho Dermatology - Coeur d'Alene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01084824
The ClinicalTrials.gov registry entry for NCT01084824 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is North Idaho Dermatology, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Verruca Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Liquid nitrogen and cantharidin is the first listed.
NCT01084824 reports 1 study location spanning 1 distinct geographic area - top geographies include Idaho.
Frequently Asked Questions
What is clinical trial NCT01084824 about?
NCT01084824 is a clinical study titled "A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin". The purpose of the study was to see if liquid nitrogen, a commonly used treatment for warts, is more effective if it is used alone, or if it is more effective if combined with cantharidin, a topical treatment also commonly used for warts (verruca vulgaris).
What is the current status of trial NCT01084824?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2007-06. Estimated completion is 2008-09.
What conditions does trial NCT01084824 study?
This clinical trial studies the following conditions: Verruca Vulgaris.
What interventions are being tested in trial NCT01084824?
The interventions under investigation include: Liquid nitrogen and cantharidin (DRUG), Liquid nitrogen and topical placebo (DRUG).
Who is sponsoring clinical trial NCT01084824?
This trial is sponsored by North Idaho Dermatology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01084824 being conducted?
This trial has 1 study location across Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Verruca Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.